Barclays raises Iovance Biotherapeutics price target to $15
Barclays maintained an Overweight rating on Iovance Biotherapeutics and raised its price target to $15.00 from $13.00, per Benzinga ratings action.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.